Acura Pharmaceuticals (ACUR) Stock Climbs On Deal With Bayer Healthcare (BAYRY)

0

Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) | Bayer AG (ADR) (OTCMKTS: BAYRY)

Acura Pharmaceuticals stock is having a great day in the market today following news of a deal made with Bayer Healthcare. Below, we’ll take a look at the deal between the two companies, talk about what we’ve seen in the market today as a result, and discuss what we can expect to see from ACUR moving forward.

ACUR & BAYRY Enter Into A License And Development Agreement

Early today, Acura Pharmaceuticals announced that it has entered into a license and development agreement with Bayer Healthcare. The agreement between the two companies revolves around Acura Pharmaceuticals’ proprietary IMPEDE technology; an advanced polymer matrix that’s used to limit or disrupt the extraction of PSE from tablets for conversion into methamphetamine. Under the agreement. The companies will develop the IMPEDE technology for use in an undisclosed methamphetamine resistant pseudoephedrine containing product in the US market. Under the new agreement, Bayer has the right to negotiate for a worldwide license to the IMPEDE technology for additional products down the road.

How Acura Pharmaceuticals Reacted To The News In The Market

As mentioned above, Acura Pharmaceuticals is having a great day in the market today following the news. In early trading, the stock rose by nearly 40% before reaching resistance and correcting. Nonetheless, ACUR is still showing great gains compared to yesterday’s close. Currently (3:32), ACUR is trading at $1.03 per share after a gain of 24.10%.

What We Can Expect To See Moving Forward

Moving forward, I’ve got an overwhelmingly bullish opinion of Acura Pharmaceuticals stock in both the short and long term views. Here’s how I see it…

  • Short Term – The news of the agreement with Bayer is great news that’s likely to send the stock flying high even further. While we are seeing declines after resistance today, what we’re seeing is normal market activity. Investors have plenty of reason to be excited; so I wouldn’t be surprised if we saw another strong breakout by the end of the week.
  • Long Term – In the long run, I’m also expecting to see great things from the stock. The agreement with Bayer will likely prove to be incredibly profitable down the road. Outside of the agreement, ACUR has a great product and is lead by a strong management team; so, it’s likely to see long run gains.

What Do You Think?

Where do you think ACUR is headed and why? Let us know in the comments below!

Image Credit

LEAVE A REPLY

Please enter your comment!
Please enter your name here